Skip to main content
. 2023 Nov 1;4:100072. doi: 10.1016/j.crimmu.2023.100072

Table 1.

Trial characteristics.

Study Trial registry identifier Study design Study location Study length Outcomes reported
Chu et al. (2016) NCT02596308 Phase 2a RCT China 3 months Immunogenicity
Safety
Frey et al. (2017) NCT01381744 Phase 1 RCT US 13 months Immunogenicity
Safety

RCT = randomised controlled trial; US = United States.